← Leaderboards
Eileen M. Barry
Albany Medical College
$25,546,080
Attributed
$33,763,048
Total exposure
18
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,763,048 · 18
By mechanism
R01$15,877,844 · 7
U19$8,480,300 · 2
U01$4,773,971 · 2
P01$3,178,314 · 4
U54$1,452,619 · 3
Top collaborators
- Wilbur H. Chen9 shared
- Karsten R.O. Hazlett7 shared
- Douglas Scott Reed7 shared
Most similar at Albany Medical College
Same institution · by research overlap
- Dennis W. Metzger$14,084,897
- Douglas Scott Reed$2,392,313
- Karsten R.o. Hazlett$3,136,768
- Edmund J Gosselin$7,026,633
- Chandra Shekhar Bakshi$1,543,222
Others in their field
Top investigators on “Attenuated”
- Lawrence Corey · Fred Hutchinson Cancer Center$124,686,255
- Stephen Lev Hoffman · Sanaria, Inc.$61,062,195
- Robert M. Grant · J. David Gladstone Institutes$48,731,024
- Jerri Edwards · University Of South Florida$42,327,407
- John C S Breitner · Johns Hopkins University$38,118,097
- Michael W Weiner · Northern California Institute Res &Educ$36,929,917
Research focus
AttenuatedPathogenImmune ResponseVaccinesVaccine CandidateAnimal ModelShigellaResponseGenesVaccine DevelopmentChildDeveloping CountriesInfectionFundingClinical TrialsAntigensEngineeringSeriesCellsEvaluationImmunizationShigella VaccinesMutationSafety
Grant awards (57)
Advanced Development of a Combined Shigella-ETEC Vaccine$1,098,552
R01 · FY2025 · AI · contact PI
Translation of a highly protective tularemia vaccine to the NHP model$787,600
R01 · FY2025 · AI
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development$418,362
P01 · FY2025 · AI · contact PI
Advanced Development of a Combined Shigella-ETEC Vaccine$1,115,547
R01 · FY2024 · AI · contact PI
Translation of a highly protective tularemia vaccine to the NHP model$824,845
R01 · FY2024 · AI
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development$380,873
P01 · FY2024 · AI · contact PI
Advanced Development of a Combined Shigella-ETEC Vaccine$1,053,471
R01 · FY2023 · AI · contact PI
An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease$973,438
U19 · FY2023 · AI · contact PI
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.$715,435
U01 · FY2023 · AI
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development$384,547
P01 · FY2023 · AI · contact PI
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development$25,879
P01 · FY2023 · AI · contact PI
An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease$638,173
U19 · FY2022 · AI · contact PI
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development$338,756
P01 · FY2022 · AI · contact PI
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.$1,529,187
U01 · FY2021 · AI
An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease$803,296
U19 · FY2021 · AI · contact PI
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development$377,115
P01 · FY2021 · AI · contact PI
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.$1,391,457
U01 · FY2020 · AI
An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease$775,033
U19 · FY2020 · AI · contact PI
Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia Model$707,956
R01 · FY2020 · AI
Modeling the Pathogenic Processes of Shigella in the Human Colonoid$262,650
P01 · FY2020 · AI · contact PI
Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia Model$714,959
R01 · FY2019 · AI
An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease$588,195
U19 · FY2019 · AI · contact PI
Good Manufacturing Practices Master Cell and Working Cell Banks and GMP Pilot Lot of Prototype Shigella flexneri 2a live vector expressing enterotoxigenic E. coli antigens, CVD 1208S 122$445,597
R01 · FY2019 · AI · contact PI
Modeling the Pathogenic Processes of Shigella in the Human Colonoid$260,658
P01 · FY2019 · AI · contact PI
Good Manufacturing Practices Master Cell and Working Cell Banks and GMP Pilot Lot of Prototype Shigella flexneri 2a live vector expressing enterotoxigenic E. coli antigens, CVD 1208S 122$1,062,611
R01 · FY2018 · AI · contact PI
Shigella Live Vector-Based Multivalent Vaccine$924,842
U19 · FY2018 · AI · contact PI
Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia Model$735,765
R01 · FY2018 · AI
Modeling the Pathogenic Processes of Shigella in the Human Colonoid$262,650
P01 · FY2018 · AI · contact PI
Good Manufacturing Practices Master Cell and Working Cell Banks and GMP Pilot Lot of Prototype Shigella flexneri 2a live vector expressing enterotoxigenic E. coli antigens, CVD 1208S 122$963,769
R01 · FY2017 · AI · contact PI
Shigella Live Vector-Based Multivalent Vaccine$925,332
U19 · FY2017 · AI · contact PI
Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia Model$732,824
R01 · FY2017 · AI
Modeling the Pathogenic Processes of Shigella in the Human Colonoid$262,650
P01 · FY2017 · AI · contact PI
Shigella Live Vector-Based Multivalent Vaccine$921,494
U19 · FY2016 · AI · contact PI
Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia Model$789,784
R01 · FY2016 · AI
Modeling the Pathogenic Processes of Shigella in the Human Colonoid$204,174
P01 · FY2016 · AI · contact PI
Shigella Live Vector-Based Multivalent Vaccine$975,452
U19 · FY2015 · AI · contact PI
Advancement of a Defined, Protective, Live Attenuated Tularemia Vaccine$713,081
R01 · FY2015 · AI · contact PI
Shigella Live Vector-Based Multivalent Vaccine$955,045
U19 · FY2014 · AI · contact PI
Advancement of a Defined, Protective, Live Attenuated Tularemia Vaccine$707,728
R01 · FY2014 · AI · contact PI
Advancement of a Defined, Protective, Live Attenuated Tularemia Vaccine$683,119
R01 · FY2013 · AI · contact PI
Broad spectrum enteropathogen vaccine development$236,466
U54 · FY2013 · AI · contact PI
Broad spectrum enteropathogen vaccine development$253,737
U54 · FY2012 · AI · contact PI
Broad spectrum enteropathogen vaccine development$231,696
U54 · FY2011 · AI · contact PI
Advancement of New Live Attenuated F. Tularensis Type A Vaccine Strains$570,316
U01 · FY2010 · AI · contact PI
Broad spectrum enteropathogen vaccine development$216,650
U54 · FY2010 · AI · contact PI
Advancement of New Live Attenuated F. Tularensis Type A Vaccine Strains$567,576
U01 · FY2009 · AI · contact PI
Shigella dysenteriae vaccine construction$353,635
R01 · FY2009 · AI · contact PI
Advancement of F. tularensis live attenuated typed A vaccine strains$230,002
U54 · FY2009 · AI · contact PI
Broad spectrum enteropathogen vaccine development$201,392
U54 · FY2009 · AI · contact PI
Shigella dysenteriae vaccine construction$353,635
R01 · FY2008 · AI · contact PI
New Opportunities - Formulation of Francisella Live Attenuated Vaccine Strains$82,676
U54 · FY2008 · AI · contact PI
Shigella dysenteriae vaccine construction$360,484
R01 · FY2007 · AI · contact PI
Conserved pneumococcal protein live-vector vaccine$316,810
R01 · FY2007 · AI · contact PI
Shigella dysenteriae vaccine construction$364,945
R01 · FY2006 · AI · contact PI
Conserved pneumococcal protein live-vector vaccine$326,272
R01 · FY2006 · AI · contact PI
Conserved pneumococcal protein live-vector vaccine$334,125
R01 · FY2005 · AI
Conserved pneumococcal protein live-vector vaccine$330,730
R01 · FY2004 · AI